Office Action Predictor
Last updated: April 16, 2026
Application No. 19/344,450

BTK DEGRADER AND USE THEREOF

Non-Final OA §101§DP
Filed
Sep 29, 2025
Examiner
VAJDA, KRISTIN ANN
Art Unit
1622
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ascentage Pharma Group CORP Limited
OA Round
2 (Non-Final)
84%
Grant Probability
Favorable
2-3
OA Rounds
1y 9m
To Grant
95%
With Interview

Examiner Intelligence

Grants 84% — above average
84%
Career Allow Rate
1331 granted / 1581 resolved
+24.2% vs TC avg
Moderate +10% lift
Without
With
+10.5%
Interview Lift
resolved cases with interview
Fast prosecutor
1y 9m
Avg Prosecution
36 currently pending
Career history
1617
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
11.2%
-28.8% vs TC avg
§102
27.5%
-12.5% vs TC avg
§112
33.6%
-6.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1581 resolved cases

Office Action

§101 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-30 are pending in the instant application. Claims 26-30 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to non-elected subject matter. The withdrawn subject matter is patentably distinct from the elected subject matter as it differs in structure and element and would require separate search considerations. In addition, a reference which anticipates one group would not render obvious the other. Claims 1-25 are rejected. Information Disclosure Statement The information disclosure statement filed on September 29, 2025 has been considered and a signed copy of form 1449 is enclosed herewith. Election/Restrictions Applicant’s election without traverse of Group I, claims 1-25, and the species Compound No. 105 in the response filed on December 17, 2025 is acknowledged. Upon further search and consideration, the election of species requirement has been withdrawn (i.e., the full scope of the subject matter of claims 1-25 has been searched and examined in its entirety). The restriction requirement (between the inventions or groups) is still deemed proper, however, and is hereby made final. Double Patenting A rejection based on double patenting of the “same invention” type finds its support in the language of 35 U.S.C. 101 which states that “whoever invents or discovers any new and useful process... may obtain a patent therefor...” (Emphasis added). Thus, the term “same invention,” in this context, means an invention drawn to identical subject matter. See Miller v. Eagle Mfg. Co., 151 U.S. 186 (1894); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Ockert, 245 F.2d 467, 114 USPQ 330 (CCPA 1957). A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101. Claims 1-25 are provisionally rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-25 of copending Application No. 19/292,469 (reference application). The claims of the instant application and the reference application are identical. This is a provisional statutory double patenting rejection since the claims directed to the same invention have not in fact been patented. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to KRISTIN ANN VAJDA whose telephone number is (571)270-5232. The examiner can normally be reached Mon-Fri 6:00-4:00. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James Alstrum-Acevedo can be reached at 571-272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /KRISTIN A VAJDA/Primary Examiner, Art Unit 1622
Read full office action

Prosecution Timeline

Sep 29, 2025
Application Filed
Jan 16, 2026
Non-Final Rejection — §101, §DP
Mar 24, 2026
Response Filed
Apr 13, 2026
Final Rejection — §101, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600712
AMINO-PYRIMIDINE AMIDES
2y 5m to grant Granted Apr 14, 2026
Patent 12600745
PROCESS FOR PREPARING B-[(7a, 1713)-17-HYDROXY-7-[9-[(4,4,5,5,5-PENTAFLUOROPENTYL)SULFINYL]NONYL]ESTRA-1,3,5(10)-TRIEN-3-YL]-BORONIC ACID
2y 5m to grant Granted Apr 14, 2026
Patent 12590094
COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE AND METABOLIC DISORDERS
2y 5m to grant Granted Mar 31, 2026
Patent 12590111
FLAVONOID DERIVATIVE FOR TREATING DENTAL CARIES
2y 5m to grant Granted Mar 31, 2026
Patent 12590093
INDOLO[2',3':3,4]PYRIDO[2,1-B]QUINAZOLINE COMPOUND AND USE THEREOF
2y 5m to grant Granted Mar 31, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

2-3
Expected OA Rounds
84%
Grant Probability
95%
With Interview (+10.5%)
1y 9m
Median Time to Grant
Moderate
PTA Risk
Based on 1581 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in for Full Analysis

Enter your email to receive a magic link. No password needed.

Free tier: 3 strategy analyses per month